We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Integrated DNA Technologies Expands into Clinical Diagnostics

By LabMedica International staff writers
Posted on 27 Mar 2026

Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings and its strategic entry into the NGS IVD market. Powered by the Archer platform technology, the IVD solutions are being introduced in the United States and select European countries. The launch is positioned to fill a gap for standardized workflows in oncology diagnostics and to support molecular pathology laboratories with quality, regulatory compliance, and clinical impact.

Both assays are built on IDT’s proprietary Anchored Multiplex PCR (AMP) chemistry, enabling targeted DNA and RNA sequencing with an emphasis on ease of use and laboratory efficiency. Each kit includes color‑coded, technician‑ and robot‑friendly reagents, adapters, and magnetic cleanup beads designed to simplify setup. In addition, key workflow steps can run in parallel, supporting efficient and straightforward library preparation for NGS.


Image: IDT’s Archer IVD Assay portfolio is built on easy-to-use Anchored Multiplex PCR technology (photo courtesy of IDT)
Image: IDT’s Archer IVD Assay portfolio is built on easy-to-use Anchored Multiplex PCR technology (photo courtesy of IDT)

Amid changing regulatory requirements in the United States and Europe, the introduction is intended to provide continuity for laboratories as they navigate increasingly complex biomarker landscapes in both routine and high‑stakes clinical settings. IDT plans to continue expanding its Archer IVD portfolio with future launches based on anchored multiplex PCR, aiming for broader access to Archer NGS assay capabilities, including novel fusion and complex variant detection for challenging sample types.

“At IDT, we believe that precision diagnostics should be as reliable as they are innovative,” said Ajay Gannerkote, president, IDT. “This launch reflects our commitment to supporting clinical labs with trusted solutions that combine innovative technology, ease-of-use, and regulatory assurance, so clinicians can focus on their mission-critical work to find the right answers across the expanding biomarker landscape.”

Related Links
Integrated DNA Technologies (IDT)


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter

Latest Industry News

GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
26 Mar 2026  |   Industry

Global Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
26 Mar 2026  |   Industry

Takara Bio USA and Hamilton Partner to Automate NGS Library Preparation
26 Mar 2026  |   Industry